News | January 28, 2022
Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
The vaccines are currently only authorised for emergency use in the country
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Subscribe To Our Newsletter & Stay Updated
